StockIQ.techJazz Pharmaceuticals plc (JAZZ) Stock Analysis
Free AI-powered analysis and research for Jazz Pharmaceuticals plc stock
Sector: Healthcare
JAZZ snapshot
Data as of 3 Nov 2026 close. Updated daily.
Jazz Pharmaceuticals plc scores 100/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 75% of its 52-week range, up 67.7% over the past year. Latest reported figures show a profit margin of 20.4%, return on equity of 22.1% and revenue growth of +15.5%.
What is driving the score
- Mixed Trend: +0
- MACD Bullish: +8
- Low P/E (14.8): +10
- Strong Revenue Growth (15.5%): +8
- Excellent Profit Margin (20.4%): +10
- Excellent ROE (22.1%): +8
- Above MA200: +4
- Strong Rise (+67.7% over 1 year): +10
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full JAZZ report
Jazz Pharmaceuticals plc (JAZZ) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze JAZZ Now →📰 Latest Update
Jazz: Q3 Earnings Snapshot
Tue, November 3, 2026 at 4:29 AM UTC 3 min read
Jazz Pharmaceuticals PLC (JAZZ) reported a loss of $483.4 million, or $7.48 per share, in its third quarter, which was greater than Wall Street expectations. Adjusted losses were $3.88 per share, while revenue reached $1.24 billion, surpassing forecasts of $1.21 billion. The company anticipates full-year revenue between $4.78 billion and $4.85 billion.